Inhibrx presents Phase 2/3 HexAgon-HN study of ordastobart plus pembrolizumab at ESMO 2026

By Public Technologies
  • Inhibrx outlined upcoming conference presentations that will disclose new reads from mid- to late-stage oncology studies.
  • Primary analysis from the Phase 2 portion of HexAgon-HN will be presented Oct. 25, 2026 at ESMO in Madrid.
  • Secondary efficacy outcomes from the Phase 2 ChonDRAgon study in conventional chondrosarcoma are slated for Oct. 29, 2026 at MSTS.
  • Updated subgroup findings and progression-free survival from ChonDRAgon will be presented Nov. 20, 2026 at CTOS in Seoul.
  • Early clinical results from an INBRX-109 combination study in Ewing sarcoma are scheduled for a Nov. 19, 2026 poster at CTOS.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA71319) on October 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.